| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Neuraminidase (sialidase), including viral (influenza), bacterial, and mammalian neuraminidases. DANA acts as a competitive inhibitor by mimicking the transition state of sialic acid cleavage, binding to the active site of neuraminidase and preventing the removal of sialic acid from glycoproteins and glycolipids.
|
|---|---|
| ln Vitro |
N-acetyl-2,3-dehydro-2-Deoxyneuramine Acid (Neu5Ac2en) at concentrations between 10 and 100 μM strongly suppresses the activity of sialidase in INS-1D cells [4].
In vitro, DANA inhibits viral, bacterial, and mammalian neuraminidase activity. It is a specific endogenous neuraminidase inhibitor used to study the roles of endogenous neuraminidase in the development and function of neural processes and pathways, as well as other processes that depend upon sialylation-desialylation cycles. The compound serves as a tool for investigating neuraminidase function in various biological systems. |
| ln Vivo |
In mouse models, N-acetyl-2,3-dehydro-2-Deoxyneuramine Acid (Neu5Ac2en) (10 mg/kg; i.p.; daily) decreases lung fibrosis[3].
In vivo activity data for DANA are available from studies investigating neuraminidase function. As a neuraminidase inhibitor, it has been used to elucidate the roles of sialidases in neural development, immune regulation, and disease processes. However, detailed in vivo efficacy data are not extensively documented in the available literature. The compound is primarily used as a research tool rather than a therapeutic agent. |
| Enzyme Assay |
Neuraminidase inhibition is measured using a fluorometric or colorimetric assay with a fluorogenic sialic acid substrate (e.g., 4-methylumbelliferyl-N-acetylneuraminic acid, MU-NANA). The enzyme (viral, bacterial, or mammalian neuraminidase) is incubated with the substrate and varying concentrations of DANA. The IC50 is determined by measuring the reduction in fluorescence or absorbance upon substrate cleavage.
|
| Cell Assay |
DANA is used in cell-based assays to study neuraminidase function. Cells are treated with DANA at varying concentrations, and neuraminidase activity is measured in cell lysates using fluorogenic substrates. The effects of neuraminidase inhibition on cellular processes such as neural development, immune cell function, or viral infection are assessed by appropriate downstream assays (e.g., neurite outgrowth, cytokine production, viral titer).
|
| Animal Protocol |
Animal/Disease Models: Mice (Mouse model of pulmonary fibrosis)[3]
Doses: 10 mg/kg Route of Administration: Ip; daily (starting at day 10 after Bleomycin, and then euthanized at day 21) Experimental Results: Inhibition of sialidases starting at day 10 after bleomycin attenuates fibrosis. Specific in vivo protocols for DANA vary depending on the biological question. For neural development studies, DANA may be administered via injection in animal models, and effects on neuronal differentiation or synaptic plasticity are assessed. For viral infection studies, DANA is used as a reference inhibitor to compare with other neuraminidase inhibitors. Dosing regimens are determined based on the specific experimental model. |
| ADME/Pharmacokinetics |
DANA has molecular formula C11H17NO8 and molecular weight 291.25. It is also known as N-acetyl-2,3-didehydro-2-deoxyneuraminic acid (NADNA). CAS number is 24967-27-9. The compound is a transition-state analog of sialic acid. Its pharmacokinetic properties are not extensively characterized as it is primarily used as a research tool. Purity is typically 98-99%.
|
| Toxicity/Toxicokinetics |
No comprehensive toxicity data are specifically reported for DANA. As a research-grade neuraminidase inhibitor, its safety profile has not been extensively characterized for therapeutic applications. Standard laboratory safety precautions should be followed when handling the compound. It is not intended for human or veterinary use.
|
| References |
|
| Additional Infomation |
2-Deoxy-2,3-Dehydro-N-acetylneuraminic acid is a product formed by the reduction of N-acetylneuraminic acid at the 2,3-dicarbon sugar bond, resulting in the loss of the C-2 hydroxyl group. It is present in relatively low amounts in body fluids but abundant in salivary urine. It is the conjugate acid of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.
2,3-Dehydro-2-deoxy-N-acetylneuraminic acid (Neu5Ac2en, DANA, NADNA) is a specific endogenous neuraminidase (sialidase) inhibitor used in biochemical and antiviral research. It is a transition-state analog of sialic acid that inhibits neuraminidases from viral, bacterial, and mammalian sources. The compound is used to study sialylation-desialylation cycles, neural development, and immune function. It is for research use only and has not entered clinical trials or received FDA approval. |
| Molecular Formula |
C11H17NO8
|
|---|---|
| Molecular Weight |
291.25
|
| Exact Mass |
291.095
|
| CAS # |
24967-27-9
|
| PubChem CID |
65309
|
| Appearance |
White to off-white solid powder
|
| Density |
1.58g/cm3
|
| Boiling Point |
773.4ºC at 760 mmHg
|
| Melting Point |
227-228ºC
|
| Flash Point |
421.6ºC
|
| Vapour Pressure |
1.27E-27mmHg at 25°C
|
| Index of Refraction |
1.612
|
| LogP |
-2.5
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
409
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)O
|
| InChi Key |
JINJZWSZQKHCIP-UFGQHTETSA-N
|
| InChi Code |
InChI=1S/C11H17NO8/c1-4(14)12-8-5(15)2-7(11(18)19)20-10(8)9(17)6(16)3-13/h2,5-6,8-10,13,15-17H,3H2,1H3,(H,12,14)(H,18,19)/t5-,6+,8+,9+,10+/m0/s1
|
| Chemical Name |
(2R,3R,4S)-3-acetamido-4-hydroxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 33.33 mg/mL (114.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4335 mL | 17.1674 mL | 34.3348 mL | |
| 5 mM | 0.6867 mL | 3.4335 mL | 6.8670 mL | |
| 10 mM | 0.3433 mL | 1.7167 mL | 3.4335 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
